Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Tirzepatide and a rash: one case report
A 2026 JAAD case report links a year of tirzepatide to a widespread rash that cleared when the drug stopped. One patient is not a risk rate.
Tirzepatide: 17% weight loss in real care
A 107-patient Spanish cohort reports 17.21% mean weight loss on tirzepatide at six months, at a median 7.5 mg dose. There is no control arm.
Why weight loss stalls on tirzepatide
A weight loss plateau is the expected shape of the tirzepatide curve, not a failure. Here is what the trials show and where retatrutide really stands.
BPC-157, gentamicin and the rat kidney
A 2026 Zagreb rat study says BPC-157 blunted gentamicin kidney damage. Here is what a rodent nephrotoxicity result can and cannot tell a human reader.
Does the eGFR dip explain heart benefit?
A 376-patient Saudi cohort asked whether the early eGFR change explains heart outcomes on dapagliflozin plus semaglutide. The answer was no.
GLP-1 timing and pregnancy blood pressure
A 2026 meta-analysis of three cohorts found no significant link between GLP-1 use around conception and hypertensive disorders of pregnancy.
Why a peptide vial freezes in the fridge
A fridge that runs too cold can freeze one vial and leave the next one liquid. Here is the physical chemistry, and what a freeze does to a peptide.
Semaglutide meta-analysis: what it adds
A 2026 pooled analysis of four semaglutide trials in non-diabetic obesity lands on almost exactly the number STEP 1 reported in 2021.
GLP-1 and mood drugs: reading the signal
A 2026 Australian study links GLP-1 starts to fewer antidepressant starts. The design behind it decides how much that finding is worth.
Tesamorelin's HIV lipodystrophy evidence
Two 2026 meta-analyses pooled the tesamorelin trials in HIV-associated lipodystrophy. Here is what they found on visceral fat, and where they disagree.
Tirzepatide and pancreatitis: one case
A 2026 case report describes tirzepatide used after recurrent hypertriglyceridemia-mediated pancreatitis. One patient is not evidence of safety.
Japan tirzepatide dispensing and dose mix
Japan's claims data show 86.2% of tirzepatide kits dispensed outside medical institutions, with higher strengths nearly doubling their share in ten months.